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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenera-
tive disease that results in death from respiratory failure. No
cure exists for this devastating disease, but therapy that directly
targets the respiratory system has the potential to prolong sur-
vival and improve quality of life in some cases of ALS. The
objective of this study was to enhance breathing and prolong
survival by suppressing superoxide dismutase 1 (SOD1) expres-
sion in respiratory motor neurons using adeno-associated virus
(AAV) expressing an artiﬁcial microRNA targeting the SOD1
gene. AAV-miRSOD1 was injected in the tongue and intrapleu-
ral space of SOD1G93A mice, and repetitive respiratory and
behavioral measurements were performed until the end stage.
Robust silencing of SOD1 was observed in the diaphragm
and tongue as well as systemically. Silencing of SOD1 pro-
longed survival by approximately 50 days, and it delayed weight
loss and limb weakness in treated animals compared to un-
treated controls. Histologically, there was preservation of the
neuromuscular junctions in the diaphragm as well as the num-
ber of axons in the phrenic and hypoglossal nerves. Although
SOD1 suppression improved breathing and prolonged sur-
vival, it did not ameliorate the restrictive lung phenotype. Sup-
pression of SOD1 expression in motor neurons that underlie
respiratory function prolongs survival and enhances breathing
until the end stage in SOD1G93A ALS mice.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating, untreatable
neurodegenerative disease. Patients with ALS die 3–5 years after diag-
nosis from respiratory failure, and death is accelerated if the bulbar
muscles and motor neurons are affected early in the disease.1 Bulbar
involvement leads to recurrent aspiration, choking, and aggravation
of respiratory disease.2,3 The most severely affected bulbar muscle is
the tongue,4 which atrophies as a result of loss of the hypoglossal mo-
tor neurons and neuromuscular junction (NMJ) disruption.5–7 In
addition to tongue involvement, all individuals afﬂicted with ALS
develop progressive diaphragm and intercostal weakness that results
in inadequate ventilation and respiratory failure.8–10 As a result of the
tongue and respiratory pathology, patients progressively develop
decreased exercise tolerance, shortness of breath, early morning head-
aches, and excessive daytime sleepiness. The rate of decline in respi-
ratory function is directly related to mortality.11–13 Furthermore, res-
piratory support with non-invasive positive pressure ventilation
signiﬁcantly prolongs survival.12,14
Approximately 5%–10% of ALS is familial, and 20% of familial ALS is
due to mutations in the gene encoding Cu/Zn superoxide dismutase 1
(SOD1).15 The exact mechanism of the SOD1-induced neurotoxicity
is unclear, but aggregations of mutant SOD1 result in a cascade of
events that eventually leads to neuronal degeneration. The SOD1G93A
mouse is the most commonly used ALS mouse model. It ubiquitously
expresses the human SOD1 gene with the G93A mutation16 and re-
capitulates ALS pathophysiology, including motor neuron loss,
axonal degeneration, muscle denervation, and limb paralysis.16–18
In addition, this mouse model has signiﬁcant respiratory insufﬁ-
ciency, restrictive lung disease, and hypoventilation.18 Furthermore,
the SOD1G93A mouse has orolingual motor deﬁcits that initially
appear as tongue motility abnormalities and then progress to tongue
force weakness.19–21 This pathology signiﬁcantly impacts breathing
because the tongue genioglossal muscle contracts during breathing
and maintains upper airway patency in the face of the negative intra-
thoracic pressure that occurs with each breath.
There is no cure for ALS. Novel therapies aimed at silencing SOD1
include inhibitory short hairpin RNA, artiﬁcial microRNA (miRNA),
and anti-sense oligonucleotides. Our group recently reported success-
ful silencing of SOD1 in mice and non-human primates using
adeno-associated virus (AAV) gene therapy encoding a miRNA
(AAV-miRSOD1).22–24 When injected into neonatal mice, survival
was prolonged by 69 days,22 whereas a systemic injection in adult
mice resulted in extension of lifespan by 22–27 days.23 Despite this
systemic therapy, respiratory insufﬁciency persisted.22,23 We hypoth-
esized that these animals eventually died of respiratory failure.
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Therefore, the goal of this study was to evaluate the impact of gene-
silencing therapy targeted to respiratory motor units on breathing
and survival, with the ultimate goal of using this as an adjunct therapy
to systemic or intrathecal delivery. Since respiratory support in ALS
patients prolongs survival, we hypothesized that suppression of
SOD1 expression in motor neurons that underlie respiration would
prolong survival. We used a combination of intralingual (speciﬁcally
genioglossal) and intrapleural AAV-miRSOD1 injections exploiting
intramuscular delivery and retrograde axonal transport to target the
entire motor unit: muscle, NMJ, motor axon, and motor neurons.
The tongue genioglossal delivery targets both the muscle and hypo-
glossal motor neurons,25,26 while intrathoracic delivery targets the
diaphragm and intercostal muscles as well as the phrenic and thoracic
motor neurons.27 Our ultimate goal was to reduce expression of the
mutant SOD1 in the tongue and respiratory motor units and thereby
enhance breathing and prolong survival.
RESULTS
To assess the beneﬁt of respiratory-targeted gene therapy for ALS, we
injected the SOD1G93A mutant mouse model with 1  1011 vector
genomes (vg) via an intralingual injection and 1  1011 vg via an in-
trapleural injection of AAVrh.10 encoding an artiﬁcial microRNA
targeting SOD1 (AAV-miRSOD1). SOD1G93A animals were injected
as adults at approximately 60 days of age with the therapeutic vector,
AAV-miRSOD1, or saline, and non-transgenic littermate animals were
used as additional controls. All animals were followed longitudinally
until they were not able to right themselves within 30 s after being
placed on either side.
Respiratory-Directed Therapy Results in Efficient Muscle and
CNS Transduction as well as SOD1 mRNA Levels Silencing
To assess the level of transduction and SOD1 mRNA silencing, we
evaluated vector genome expression in treated SOD1G93A mice.
Efﬁcient targeting of the AAV-miRSOD1 vector was observed in
the tongue, intercostal muscles, lung, and diaphragm (Figure 1A).
To assess the extent of systemic distribution, we examined vector
genome levels in the liver, heart, and hindlimb. Injections targeting
the tongue and thoracic cavity led to a considerable amount of vec-
tor genomes in the liver, heart, and hindlimb (Figure 1B). Vector
genomes were also detected in the medulla and throughout the
entire spinal cord (Figure 1C). To assess retrograde transport to
the hypoglossal nucleus and phrenic motor nucleus by intralingual
and intrathoracic injections, we injected SOD1G93A mice with an
AAVrh10 vector containing GFP. At the end stage in the SOD1G93A
Figure 1. Intralingual and Intrathoracic Injections of AAV-miRSOD1 Are Systemically Distributed and Lead to Widespread Suppression of SOD1 Expression
(A–F) Quantitative PCR estimates of vector genomes are shown in (A) peripheral tissues (liver, heart, hindlimb), (B) respiratory muscles, and (C) four regions of the CNS.
qRT-PCR estimates of levels of SOD1mRNA are illustrated for extracted (D) peripheral tissues (liver, heart, hindlimb), (E) respiratory muscles, and (F) four regions of the CNS.
Error bars represent ± standard error of the mean (SEM) (A–C) and ± positive and negative error (D–F). n = 4, Student’s t test to determine significance in (D)–(F) comparing
untreated to treated. *p < 0.005.
www.moleculartherapy.org
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mice we observed GFP staining of motor neurons in the hypo-
glossal motor nucleus and phrenic motor nucleus, respectively
(Figure S1).
Next, we evaluated mRNA expression levels in treated and un-
treated SOD1G93A mice. Transduction within the tongue and respi-
ratory muscles led to robust silencing of SOD1 mRNA by 64% in
the tongue and 80% in the diaphragm (Figure 1D).The lung had
a more modest reduction of SOD1 mRNA (35%). Efﬁcient silencing
was also observed systemically, as evidenced by a decrease in
expression by 86%, 87%. and 89%, in the liver, heart, and hindlimb,
respectively (Figure 1E). Suppression of SOD1 mRNA was also
observed in the medulla and spinal cord ranging from 23% to
45% (Figure 1F).
Delayed Disease Onset and Prolonged Survival in AAV-miRSOD1-
Treated SOD1 Mice
Animal strength and behavior were assessed every 30 days until dis-
ease onset and then every week thereafter. AAV-miRSOD1 therapy tar-
geting the respiratory system signiﬁcantly enhanced survival by an
average of 50 days in treated compared to untreated SOD1G93A mice
(Figure 2A).Weight loss, neurological symptoms, andmuscle strength
were also assessed. A signiﬁcant improvement in weight gain was
Figure 2. AAV-miRSOD1-Treated Animals Show
Increased Survival and Improved Maintenance of
Weight and Strength
(A) A Kaplan-Meier percent survival plot documents an
increase in 36% cumulative survival of 50 days in AAV-
mirSOD1 mice. Survival logrank (Mantel-Cox) test, p <
0.0001. (B) Percent change in body weight plotted from day
60 until endpoint. (C) Changes in the neurological screening
from day 60 to endpoint. This ranges from 0 (the mouse
appears normal) to 4 (the mouse cannot right itself within
30 s of being placed on either side). (D) Four-limb grip
strengthmeasured in centinewtons (cN). (E) Inverted screen
hanging test time, plotted to a maximum of 120 s. With the
exception of (A), data are represented as mean ± SEM; a
one-way ANOVA was performed for each time point, p <
0.05. Multiple comparisons between groups were per-
formed using the Fisher’s least significant difference (LSD)
test. N = 8 at start of experiment; N/8 is listed for each time
point for SOD1- and mir-treated animals. For non-trans-
genics (NTGs), n was the following at each time point (not
from humane endpoint but for age-matched controls):
160 days, n = 7; 175 days, n = 6; 190 days, n = 3. *p < 0.05,
significantly different from NTG littermates; #p < 0.05,
significantly different from untreated SOD1.
observed in treated compared to untreated
SOD1G93A mice, with some treated mice main-
taining weight until 190 days of life (Figure 2B).
Neurological screening using a standard ALS
neurological screening metric28 revealed that,
compared to untreated SOD1G93A mice, AAV-
miRSOD1-treated SOD1G93A mice had a slower
neurological decline (Figure 2C). A four-limb grip strength test
(Figure 2D) and inverted screen testing (Figure 2E) revealed less rapid
deterioration of muscle strength in AAV-miRSOD1-treated mice
compared to untreated SOD1G93A mice. Overall, AAV-miRSOD1-
treated SOD1G93A mice showed enhanced survival, weight gain, and
neurological improvement.
Enhancement of Breathing in AAV-miRSOD1-Treated SOD1G93A
Mice
Whole-body plethysmography (WBP) was used to assess the ther-
apeutic beneﬁts of tongue and respiratory-directed AAV-miRSOD1
on respiratory function. WBP measures frequency, lung volumes,
and ﬂow rates in awake spontaneously breathing animals. At
90 days and 130–149 days, no signiﬁcant differences in breathing
parameters were observed between the treated and untreated
SOD1G93A mice or between the SOD1G93A and non-transgenic lit-
termates (Figures 3A–3E). At the ﬁnal time point from 150 to
169 days, few untreated animals remained (n = 2) and they had a
decreased respiratory rate (frequency) compared to the remaining
AAV-miRSOD1-treated SOD1G93A mice (n = 8) (Figure 3A). In
addition, the untreated SOD1G93A mice had decreased tidal vol-
umes compared to non-transgenic littermates (Figure 3B) and
decreased minute ventilation (Figure 3C) compared to both the
Molecular Therapy: Methods & Clinical Development
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AAV-miRSOD-treated SOD1G93A mice and the non-transgenic lit-
termates (for both). Untreated SOD1 mice had decreased peak
expiratory ﬂow (PEF) and decreased peak inspiratory ﬂow (PIF)
compared to non-transgenic littermates, suggesting increased
weakness in respiratory muscles (Figure 3E). Furthermore,
compared to the AAV-miRSOD1-treated SOD1G93A mice, the un-
treated mice had decreased PIF and PEF. PIF and PEF reﬂect inspi-
ratory muscle strength and expiratory muscle strength, respectively.
Thus, the AAV-miRSOD1-treated SOD1G93A mice behaved similarly
to non-transgenic littermates, in that they survived to this time
point and maintained respiratory muscle strength, frequency, tidal
volume, and minute ventilation. Thus, overall breathing decline
was attenuated in the SOD1G93A mice treated with AAV-miRSOD1,
whereas surviving untreated SOD1G93A mice had declines in several
respiratory parameters.
To assess the pulmonary mechanics of AAV-miRSOD1-treated ani-
mals, forced oscillometry techniques were used at disease endpoint.
The total respiratory resistance, central airway resistance, and tissue
resistance were all increased in both the AAV-miRSOD1-treated and
untreated SOD1G93A animals (Figures S2A–S2C). Similarly, the inspi-
ratory capacity and respiratory compliance were decreased at
endpoint in both untreated and AAV-miRSOD1-treated animals.
Thus, no signiﬁcant improvement occurs in pulmonary mechanics
in either untreated or treated SOD1G93A mice.
Preservation of Motor Neurons and Corresponding Peripheral
Synaptic Terminals
The impact of therapy on motor neuron survival was examined using
histological quantiﬁcation. Speciﬁcally, we quantiﬁed cresyl violet-
stained hypoglossal and cervical ventral motor neurons at the
endpoint (Figure 4). Non-transgenic littermates had signiﬁcantly
more motor neurons in both hypoglossal and cervical ventral regions
than both the untreated or treated animals did, suggesting that at dis-
ease endpoint motor neuron death was similar between treated and
untreated animals.
To assess the effect of respiratory-directed therapy on axonal integrity
of hypoglossal and the phrenic nerve, these were collected from
animals at the endpoint, with non-transgenic littermates being age
matched to the treated group (Figure 5). In the AAV-miRSOD1-treated
mice, there was a preservation of axonal numbers at the end stage in
the hypoglossal and phrenic nerves. However, despite the preserva-
tion of axon numbers, the size of the axons was signiﬁcantly smaller
(Figure 5D).
To assess the impact of distal nerve degeneration, we assayed theNMJs
in the tongue and diaphragm at the endpoint. Within the diaphragm,
the untreated animals revealed signiﬁcant disruption of theNMJs (Fig-
ure 6). In contrast, in the AAV-miRSOD1-treated diaphragm, there was
some preservation of presynaptic and postsynaptic components of the
Figure 3. AAV-miRSOD1 Animals Display Improvement in Breathing
Whole-body plethysmography of awake spontaneously breathing animals. Data are reported as a percentage of response to a 10-min period of hypercapnia compared to
baseline breathing. (A and B) At the untreated SOD1G93A endpoint (151–169 days), significant differences are noted between AAV-miRSOD1 in (A) frequency and NTG lit-
termates in (B) tidal volume. (C) Minute ventilation findings for both treated and NTG littermates were significantly different from untreated animals at the untreated SOD1
endpoint. (D and E) No differences were observed in (D) peak inspiratory flow between any group, but significant differences were noted between NTG littermates and
untreated animals in (E) peak expiratory flow. All data are represented asmean ±SEM. Starting numbers were n = 8 for AAV-miRSOD1, n = 5 for untreated SOD1G93A, and n = 8
for NTG. Only two untreated animals survived to the day 150–169 time point. A mixed-effects model was used to take into account missing animals that did not survive to the
later time points. Multiple comparisons between groups were performed using the Fisher’s LSD test. *p < 0.05.
www.moleculartherapy.org
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NMJ (Figure 6). Within the tongue of the untreated animals there was
signiﬁcant denervation of NMJs (Figure S3). AAV-miRSOD1 treatment
mitigated this denervation, but this improvement was not as robust as
in the diaphragm (Figure 6; Figure S3).
DISCUSSION
The most signiﬁcant outcome of this study is that targeting respira-
tory motor neurons using AAVrh.10 expressing an artiﬁcial miRNA
against the SOD1 (AAV-miRSOD1) signiﬁcantly prolongs survival in
adult SOD1G93A ALS mice. In addition, respiratory function was
Figure 4. Motor Neuron Death Is Observed in Both
Treated and Untreated SOD1 Animals
Representative images of cresyl violet staining for motor
neurons within the hypoglossal nuclei were stained from
tissues harvested at their respective endpoints: (A) un-
treated SOD1G93A animals (137 days), (C) AAV-miRSOD1-
treated SOD1G93A mice (190 days), and (E) NTG littermate
controls (192 days). (B), (D), and (F) are higher magnifica-
tions of the boxed area in panels (A), (C), and (E), respec-
tively. Scale bars for (A), (C), and (E), 100 mm; for (B), (D), and
(F), 50 mm. (G and H) Motor neuron quantification: (G) hy-
poglossal motor neuros, (H) cervical motor neurons. All data
are represented as mean ± SEM. n = 4 for AAV-miRSOD1,
n = 3 for untreated SOD1G93A, and n = 6 for NTG (n = 5 for
phrenic). A one-way ANOVA was performed with uncor-
rected Fisher’s LSD multiple comparisons test. *p < 0.05
preserved until end stage disease and disease
onset was delayed. This study highlights the
importance of treating the respiratory system
in ALS.
AAV Gene Therapy for ALS
It is difﬁcult to directly compare AAV gene ther-
apy animal studies because of variations in
injection routes, capsid variants, vector con-
structs and genomes, titration methods of
different laboratories, vector dosages, and age
of animals when treated. However, similar
studies using different routes of injection have
been performed in SOD1 mouse models with
varying results. Recent studies from our group
documented that an SOD1-targeting miRNA
delivered by AAV9 prolongs survival by
70 days in SOD1G93A mice when injected in
the neonatal period.22 In a more direct compar-
ison, our group used the same capsid and similar
vector, AAVrh.10-mir SOD1, intravenously in
adult mice and survival was only prolonged by
22–27 days.23 Similarly, a recent study using
AAVrh10 to express a small nuclear RNA that
skips exon 2 out of frame reported signiﬁcant
improvement in survival in mice treated at
both adult and neonatal ages.29 In a subset of
mice, limb function was completely preserved in their study,
comparable to our earlier observation.22 In addition, other groups
used AAV2 or AAV9 to deliver therapeutic genes, such as insulin
growth factor 1 (IGF-1)30–33 into muscles, including the muscles
of respiration. The goal of both of these studies was to use
retrograde transport of AAV to transduce the motor neurons of
interest.30,32 Both studies saw signiﬁcant enhancement in survival
at 30–37 days when the muscles of respiration, such as the inter-
costal muscles, were targeted versus 10–12 days without inter-
costal muscle injections.30,32
Molecular Therapy: Methods & Clinical Development
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AAVrh10 was an ideal choice for this present study because of its abil-
ity to cross the blood-brain barrier and to transduce motor neurons
by retrograde transport.34,35 In addition, AAVrh10 is safe and efﬁca-
cious in bothmice and non-human primate models.23,24 The utility of
AAVrh10 is underscored by proof-of-principle and safety data gener-
ated with this vector design in cynomolgus macaques.24 In our cur-
rent study, we injected 2  1011 vg of AAV expressing the miRSOD1,
which is 1/10th of the dose that was injected systemically (see Borel
et al.24) or 1/39th of the dose co-injected intracerebroventricularly
and systemically in adult mice (see Biferi et al.29), and we report an
improvement in survival by 50 days, whereas other reported
22–27 days and 63 days, respectively.
Respiratory Involvement in ALS
All individuals afﬂicted with ALS ultimately succumb to inadequate
ventilation and respiratory failure secondary to diaphragm and
intercostal muscle weakness.8–10 These muscles are essential for
breathing and are innervated by the phrenic nerve in the ventral
horn of C3–C5 and by the intercostal motor neurons in T1–T12
in the thoracic spinal cord. The largest increase in lifespan to date
in an SOD1 mouse model was reported in a study that also targeted
the respiratory muscles. Speciﬁcally, this study used a lentiviral short
hairpin RNA (shRNA) delivered by a series of intramuscular injec-
tions that included hindlimb, facial, tongue, diaphragm, and inter-
costal muscles.36 Through an intralingual and intrapleural injection
of AAV gene therapy, our goal was to target the entire motor unit of
the tongue, diaphragm, and intercostal muscles. Speciﬁcally, we
sought to target the nerves and motor neurons innervating these
muscles. Using the AAVrh10-GFP we found positive GFP staining
in the phrenic and hypoglossal motor nuclei (Figure S1). In addition,
at the end stage in AAV-miRSOD1-treated animals, we report im-
provements in NMJ in the diaphragm, and preservation of axonal
integrity of the phrenic nerve, but the survival of the hypoglossal
and cervical ventral motor neurons was not signiﬁcantly different.
Treated animals showed evidence of greater respiratory muscle
strength as seen with preserved PIF and PEF. However, motor
neuron loss and restrictive lung disease were still evident at the
end stage. We previously reported restrictive lung disease in
SOD1G93A mice.18 Unfortunately, AAV-miRSOD1 therapy targeting
the respiratory system did not prevent restrictive lung disease, and
at the end stage mice succumbed to respiratory failure. A recent
report utilizing muscle-speciﬁc kinase (MuSK) antibody therapy
preserved NMJs in the diaphragm but did not improve diaphragm
strength or breathing.37 This suggests the importance of not only
preserving the NMJ but also the motor neurons. The eventual
decline in respiratory function and restrictive lung disease may be
caused by inefﬁcient targeting of all neuronal cells present in the mo-
tor nuclei innervating the diaphragm and intercostal muscles. Thus,
combining respiratory directed and intravenous, intracerebral
ventricle, or intrathecal infusion may be necessary to treat all
neuronal cells affected. Since positive pressure ventilation enhances
survival and quality of life, combination therapy has the ability
to treat respiratory insufﬁciency and enhance survival and quality
of life.
Tongue Involvement in ALS
Patients with ALS who initially present with bulbar symptoms have a
worse prognosis and rapidly progressive disease course.1 The most
severely affected bulbar muscle is the tongue.4 These abnormalities
of the tongue are a result of atrophy due to loss of the hypoglossal mo-
tor neurons,7 which control the intrinsic and most extrinsic muscles
of the tongue.6
The hypoglossal motor neurons are also important in maintaining
upper airway patency, as these cells regulate the shape, stiffness, and
position of the tongue.6,38–40 Contraction of the extrinsic tongue mus-
cles dilate and stiffen the pharyngeal lumen and prevent collapse in the
face of negative inspiratory pressures.41,42 Thus, degeneration of hypo-
glossal motor neurons in ALS results in upper airway obstruction, oral
phase dysphagia, and recurrent aspiration. With our dual injection
strategy, we were able to signiﬁcantly silence expression of SOD1
within the tongue. Interestingly, this tongue correction correlated
with maintenance of weight and increased survival in treated animals.
Although our approach targeted the respiratory system, it is impor-
tant to note that we did see systemic distribution of virus that was
correlated with signiﬁcant reduction in SOD1 mRNA expression in
the liver, heart, and limb skeletal muscle. We think that the systemic
distribution of vectors in combination with the directed lingual treat-
ment enhanced survival in these animals. Thus, we propose that
future gene therapy approaches should consider a dual injection (sys-
temic and intralingual or intrathecal and intralingual) to ensure that
the hypoglossal motor neurons are targeted. If successful, we think
that this will allow patients better control of their tongue, mainte-
nance of upper airway patency, and decreased aspiration of secretion.
In conclusion, this study illustrates the importance of targeting the
respiratory system in the treatment of ALS. Ideally, a therapy would
target the entire CNS with focus on both motor units responsible for
respiration and ambulation. However, our directed approach clearly
demonstrates the degree to which respiratory rescue can enhance sur-
vival. In addition, a robust improvement in survival in adult animals
was documented at considerably lower doses than previously pub-
lished. Correction of hindlimb paralysis is an important functional
benchmark in treated ALS, and indeed we saw modest but signiﬁcant
improvement in limb strength in our study. However, because respi-
ratory failure is the ultimate cause of death in this disease, future ther-
apeutics should also target the respiratory system.
MATERIALS AND METHODS
Animals
All experimental procedures were approved by the Institutional Ani-
mal Care andUse Committee at the University ofMassachusetts Med-
ical School. SOD1G93A animals were randomly assigned to the
AAVrh10-H1-miRSOD1 (n = 8, 7 females, 1 male) versus the phos-
phate-buffered saline (PBS) group (N=8, 6 females, 1male). Littermate
non-transgenic controls (n = 8, 7 females, 1 male) were injected with
PBS. Injections were administered by an investigator blinded to the
groups. Mice transgene copy numbers were monitored by quantitative
www.moleculartherapy.org
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real-time-PCR according to Prize for Life and Jackson Laboratory
guidelines such that any mice with fewer than 20 copies or more
than 25 copies were excluded.
AAV Vectors and Injection Methods
AAVrh10-H1-miRSOD1 vectors (hereafter AAV-miRSOD1), targeting
the human SOD1 sequence, were generated as described.23,24 The vec-
tor construct contains mutated inverted terminal repeats (ITRs) to
create dsAAV vectors, a single miR sequence driven by the H1 pro-
moter, and a rabbit poly-globin poly(A) tail (clinical H1 construct
described in Borel et al.24). All vector doses were per animal, at
1 1011 vg or PBS, and they were injected into each location at a vol-
ume of 40 mL in the tongue and 400 mL in the intrapleural space
described for a total vector dosage of 2  1011 vg per animal.25–27
Figure 5. AAVmiRSOD1 Preserves Axons within the Hypoglossal and Phrenic Nerves
(A–F) Representative cross-sections of hypoglossal (A, C, and E) and phrenic (B, D, and F) nerves stained with toluidine blue at endpoint for treated and untreated SOD1G93A
mice at their respective endpoints and age-matched NTG littermate controls. NTG littermate (172 days) (A and B), AAV-mirSOD1(190 days) (C and D), and untreated (156 days)
(E and F). (G and H) Quantification of axons was performed within the hypoglossal (G) and phrenic (H) nerves. All data are represented as mean ± SEM. n = 3 for all groups;
one-way ANOVA was performed with an uncorrected Fisher’s LSD multiple comparisons test. *p < 0.05.
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Injections were performed by an investigator blinded to the groups
and the study drug. The intralingual injections were performed as
previously described,25 and the intrapleural injections were per-
formed as previously described.27 SOD1G93A animals were injected
at approximately 60 days of age with either AAV-miRSOD1 or PBS,
and non-transgenic littermates were used as additional controls. All
animals were followed longitudinally.
Behavior Testing
Four-limb grip strength and inverted screen testing were determined
by a an investigator blinded to the experimental groups, as previously
described.43 The four-limb grip strength test was performed using
mesh screen on an Alemno digital grip strength meter (Holzkirchen,
Germany) to determine peak force. Each grip test was repeated twice
with a 15-min rest period, and the maximum force was recorded. An
inverted screen was performed using square wire mesh rotated 180.
Animals were assessed for latency to fall up to 2 min, and again this
was repeated twice per session with a 15-min rest period, and the
longest hang time was recorded. For the neurological screening score
assessment, an investigator blinded to groups scored animals accord-
ing to Prize for Life and Jackson Laboratory guidelines based on the
following: 0, full extension of hind legs frommidline when suspended
by tail; 1, collapse of leg extension towardmidline or trembling; 2, toes
curl under at least twice when walking or any foot dragging; 3, paral-
ysis or minimal joint movement; and 4, mouse cannot right itself
within 30 s after being placed on either side.
Ventilation
Ventilation was quantiﬁed using whole-body plethysmography in un-
restrained, unanesthetized mice as previously described.18,43 Awake,
non-restrained mice were placed inside a 3.5  5.75-in Plexiglas
chamber (SCIREQ, Montreal, QC, Canada) and data were collected
in 10-s intervals. The Drorbaugh and Fenn44 equation was used to
calculate respiratory volumes, including tidal volume and minute
ventilation. Mice immediately underwent a 10-min hypercapnic chal-
lenge (fraction of inspired O2 [FiO2], 0.21; fraction of inspired CO2
[FiCO2], 0.07; nitrogen balance) followed by a subsequent 60- to
90-min eupnea period when they were exposed to normoxic air
(FiO2, 0.21; nitrogen balance).
Measures of Pulmonary Mechanics
Pulmonary mechanics were performed at the study endpoint using
forced oscillometry (FlexiVent system, SCIREQ, Montreal, QC, Can-
ada) at baseline and in response to incremental doses of methacholine
as previously described.45 In brief, animals were anesthetized with an
intraperitoneal (i.p.) injection of a mixture of ketamine (90 mg/kg,
Animal Health International) and xylazine (4.5 mg/kg, Propharma),
and a tracheotomy was performed followed by insertion of a pre-cali-
brated cannula into the trachea. Spontaneous respiratory effort was
prevented using a neuromuscular blocking agent (pancuronium
bromide, 2.5 mg/kg; Hospira, Lake Forest, IL, USA). Respiratory me-
chanics were obtained and calculated using FlexiWare software
(SCIREQ, Montreal, QC, Canada) as previously described.18,43,45,46
Vector Genomes
Genomic DNA (gDNA) was extracted using a DNeasy blood and tis-
sue kit (QIAGEN, Valencia, CA, USA) from the tissues harvested
from AAV- and PBS-injected animals at the study endpoint.43 Quan-
titative real-time PCR was carried out using custom TaqMan gene
expression master mix (Applied Biosystems) and TaqMan probes
(Applied Biosystems) for a custom probe against rabbit poly-globin
poly(A) tail (probe, 50-/56-FAM/ATGAAGCCCCTTGAGCATCT
GACTTCT/36-TAMSp/-30; primer 1, 50-GCCAAAAATTATGGGG
ACAT-30; primer 2, 50-ATTCCAACACACTATTGCAATG-30) with
a plasmid control standard curve.
Analysis of RNA Knockdown
RNAwas isolatedwith TRIzol (Invitrogen) and aDirect-zol RNAMin-
iPrep kit (Zymogen), then transcribed into complementaryDNAusing
theHigh-CapacityRNA-to-cDNAkit (AppliedBiosystems). qRT-PCR
was carried out using TaqMan gene expression master mix (Applied
Biosystems) and TaqMan probes (Applied Biosystems) for human
SOD1 (Hs00533490_m1), and mouse hypoxanthine-guanine phos-
phoribosyltransferase (Hprt; Mm01545399_m1) as normalization
gene. Relative expression was calculated as described.22
Immunostaining for NMJs
The tongue samples were embedded in optimal cutting temperature
(OCT) compound and frozen. 20-mm-thick sections were cut for
the tongue and stained by immunohistochemistry. Brieﬂy, the tissue
was incubated with alpha-bungarotoxin (Alexa Fluor 594 conjugated,
1:1,000; Invitrogen, #B-13422) for 2 h at room temperature, washed in
PBS, and then tissue was incubated at least 24 h in a mixer of the two
primary antibodies against neuroﬁlament (1:400, chicken polyclonal
to neuroﬁlament NF-H, immunoglobulin [Ig]Y; EnCor Biotech-
nology, #CPCA-NF-H) and synaptotagmin (1:200; ZNP1 synaptotag-
min, Zebraﬁsh International Research Center, znp-1 #090811). The
following day, the tissue was washed in PBS, incubated in an anti-
mouse Alexa Fluor 488 (1:200) and in anti-chicken Alexa Fluor 647
(1:1,000) secondary antibodies for at least 24 h. The sections were
washed in PBS, covered with ﬂuorescent mounting media, and cover-
slipped. Diaphragm was not sectioned and was immunostained using
the same method, except the incubation time was extended to at least
72 h at 4C.
Figure 6. AAVmiRSOD1 Preserves Neuromuscular Junctions within the Diaphragm
Neuromuscular junctions (NMJs) were analyzed in untreated SOD1G93A and AAV-miRSOD1mice at their respective endpoints and in age-matched NTG littermate controls. (A)
Immunofluorescence staining with rhodamine-conjugated a-bungarotoxin (red), as well as antibodies against anti-synaptotagmin (ZNP-1) and neurofilament-200 (gray).
Denervation of NMJs is depicted by dashed circles. Representative images for NTG littermate control (205 days), AAV-miRSOD1 (205 days), and untreated SOD1G93A
(137 days) are shown. (B) Quantification of percent innervated NMJs is depicted. All data are represented as mean ± SEM. n = 4 for AAV-miRSOD1 and untreated SOD1G93A,
and n = 5 for NTG. One-way ANOVA was performed with an uncorrected Fisher’s LSD multiple comparisons test. *p < 0.05.
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Quantification of NMJ Integrity
NMJs in tongue and diaphragm were imaged using z series maxi-
mized projection on a Leica DM5500B microscope equipped with a
40 oil objective and ﬂuorescent camera. Randomly selected equal
area images were used to evaluate integrity of presynaptic (immuno-
labeled with synaptotagmin and neuroﬁlament) and postsynaptic
(labeled with bungarotoxin) structural components of each NM junc-
tion found in the ﬁeld using the “Count” function of the Adobe Pho-
toshop software. At least 10 images of the diaphragm were analyzed
for each animal (total number of animals with diaphragm NMJ quan-
tiﬁcation: n = 4 for SOD1G93A, AAV-miRSOD1 n = 5 for non-trans-
genic; total number of animlas for tongue NMJ quantiﬁcation:
n = 4 for AAV-miRSOD1 and non-transgenic, n = 5 for SOD1G93A).
A “normal”NMJ unit was considered to have well-structured presyn-
aptic and postsynaptic components deﬁned by colocalization of axon
terminals with ﬂuorescently labeled acetylcholine receptors (AChRs).
In contrast, incomplete, or denervated, NMJs have AChR clusters on
muscle ﬁbers that are not contacted by an axon, as observed as an
absence of anti-neuroﬁlament staining.47,48
Cresyl Violet Staining and Quantification
The medulla and cervical spinal cord tissues were extracted and post-
ﬁxed by immersion in 4% paraformaldehyde for at least 48 h and then
transferred to 30% sucrose for cryoprotection and until sinking and
were embedded in OCT compound and frozen. 40-mm-thick medul-
lar and cervical spinal cord sections were mounted on glass slides and
stained with cresyl violet stain pre-warmed to 60C and coverslipped
with Permount mounting medium (Thermo Fisher Scientiﬁc, Hamp-
ton, NH, USA). Images were taken on a Leica DM5500B bright-ﬁeld
microscope. Every sixth section was counted for a total of approxi-
mately 16 sections from each region in each mouse. Obtained values
were averaged across each experimental group of animals, and the
average of motor neurons per each section was graphed.
Toluidine Blue Staining and Quantification of Axonal Numbers
The hypoglossal and phrenic nerves were ﬁxed in 2.5% glutaraldehyde
in 0.1 M sodium cacodylate buffer (pH 7.2) overnight at 4C, postﬁxed
in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, and then
embedded in epoxy resin. Blocks were trimmed to orient the nerves in
order to obtain precise 1.5-mm-thick cross-sections on a Leica Ultracut
E ultramicrotome. To quantify the number of axons, sections were
counterstained with toluidine blue and coverslipped with Permount
mounting medium (Thermo Fisher Scientiﬁc, Hampton, NH, USA)
without dehydration in ethanol and the use of xylene as described
elsewhere22. Once dried completely, slides were coverslipped with
Permount mounting medium (Thermo Fisher Scientiﬁc, Hampton,
NH, USA) without dehydration in ethanol and the use of xylene.
Images were taken on a Leica DM5500B bright-ﬁeld microscope.
The number of axons was manually quantiﬁed using PhotoShop soft-
ware. At least three mice were analyzed per experimental group.
Statistical Analysis
All statistical analyses were performed using Prism software
(version 7, GraphPad, La Jolla, CA, USA). Survival logrank
(Mantel-Cox) test was performed for survival analysis between all
four treatment groups. A two-way ANOVA was performed for
weights, strength testing, and measures of respiratory mechanics. A
mixed-effects model was used to take into account missing animals
that did not survive to the later time points. Multiple comparisons be-
tween groups and comparisons to baselines were performed using the
Fisher’s least signiﬁcant difference (LSD) test. For the vector genomes,
analysis was performed using the Student’s t test, and signiﬁcance for
the enzyme assay and ventilation data was determined by one-way
ANOVA. Signiﬁcance was considered at a p value <0.05.
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